Dialog Box

Loading...

GBM AGILE: Information for patients

Below are some frequently asked questions about GBM AGILE. We will update this page on a regular basis as new information comes to hand. If you have been diagnosed with brain cancer and want information about how to get on a clinical trial you should speak to your doctor. More information about clinical trials is available at clinicaltrials.gov

UPDATED APRIL 09, 2019

What is Cure Brain Cancer Foundation’s role in GBM AGILE and who is responsible for the trial?

Cure Brain Cancer Foundation is a stratetic partner of GBM AGILE, and we have both catalysed and provided seed funding for the project. The Global Coalition for Adaptive Research (GCAR) is responsible for running the trial globally.

How can I get on this trial?

Currently there are no trial sites named in Australia, but it is anticipated this trial will be available in metro areas. Information about the trial, including start dates will be listed on the clinical trial registries when the trial enrols.

When will it start enroling?

A number of important regulatory steps must be taken before GBM AGILE opens to patients and once they have been addressed we will provide a further update. We are determined to help make this a reality as soon as possible.

Click here for an update from December 2016.

How many people will be enrolled on this trial?

The current estimate is that, over time, around 300 Australians will be enrolled within a total of approximately 3,000 patients worldwide. 

Will I be eligible?

The protocol is currently still in development so eligibility criteria are yet to be finalised. We can confirm that this trial will only be enrolling GBM patients, but it is hoped the learnings can be applied to other disease types

What treatments will be trialed?

Regorafenib has been approved as the first agent for inclusion on the trial. More agents will be announced and assessed throughout the trial in due course. They may include immunotherapies, targeted agents and chemotherapies that are identified as promising by the ‘Agent Selection’ sub-committee.

Why is this trial only focused on GBM?

GBM or glioblastoma, a grade IV astrocytoma, is widely recognised to be one of the most common and the most deadly brain tumour in adults with most people surviving fewer than 15 months post-diagnosis.

Will children be eligible to go on the trial?

The protocol is still being developed, but it now looks unlikely that paediatric patients will be able to participate in the early stages of the trial. 

Other clinical trials for GBM patients in Australia